LabGenius
Biologics & Biosimilars · Oncology Therapeutics
Facts
as of Nov 19, 2026LabGenius Therapeutics is pioneering a closed-loop platform that combines AI, robotic automation, and synthetic biology to accelerate the discovery of next-generation therapeutic antibodies for solid tumours.
- Employees
- 51-200estimated range
- Official records
- Wikidata Q56585160
- Website
- labgeniustx.com
These are the key facts about LabGenius on Alion as of Nov 19, 2026. The latest round is Series A of $10M, announced in 2019.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
What the registers and the postings say about this employer.
Sanctions lists
OFAC SDN, EU consolidated · sanctionssearch.ofac.treas.gov ↗
No match
Phishing reports
OpenPhish, Phishing.Database · openphish.com ↗
None
Layoff notices
US WARN notices on file · dol.gov ↗
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Financials
Funding rounds, investors and revenue on record.
$10MTotal raised
Series ALatest round
1Rounds and grants
Money by yearUSD, rounds and grants
Largest rounds and grants
2019
$10M
Sources: funding announcements, grant and company registers
Money
LabGenius has $10M paid in by investors, lenders and donors.
$10MPaid in
StagePaidSignedAnnouncedSourceFiledAnnouncedPress
Money in
$10MPaid
Taxes
No public tax figures for this company or its entities.
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".
Owners & entities
Sources name Obvious Ventures, Lux Capital among the owners or investors of LabGenius.
Named investors, no share stated2
Holders and shares as each register or filing states them.
Milestones
Dec 2024
Website went live first capture in the Wayback Machine
Nov 16, 2022
Oct 28, 2019
Raised a round Series A $10M · led by Lux Capital · Pulse 2.0
Each milestone is dated by its source: registers, filings, the press
